British drugmaker GlaxoSmithKline will seek marketing approval for the world's first malaria vaccine next year after trial data showed the shot significantly cut cases of the disease in African children.
"It has come to our knowledge that in the major pockets of the country our products are not being purchased by the traders from September 15, 2013. On account of the above, sales of the company continue to be affected," the company said in a
The consumer arm of British pharma major, GlaxoSmithKline (GSK), is extending its popular antacid Eno, used to cure acidity and other gastric issues, into tablets and liquids in a bid to take on rivals such as Digene from Abbott and Gelusil from Pfizer.
GlaxoSmithKline Plc, the drugmaker being investigated in China for alleged bribery, is the latest foreign company to come under government scrutiny as Premier Li Keqiang tries to assuage anger over consumer safety breaches.
India's GlaxoSmithKline Pharmaceuticals is down 4.3 per cent after Nomura downgraded the stock by a notch to "reduce" from "neutral", citing the impact from the government's recent price controls and decreasing likelihood of an open
GlaxoSmithKline Pharmaceuticals (GSK Pharma) delivered December 2012 quarter results largely in line with expectations. The company grew its sales at a healthy 16% driven by new product launches across product categories.
GlaxoSmithKline Pharmaceuticals today reported a 1.29 per cent rise in its net profit at Rs 138.51 crore for the quarter ended December 31, 2012.The company had posted a net profit of Rs 136.74 crore for the corresponding period previous fiscal, the
India is not the only market where the London-headquartered GlaxoSmithKline (GSK) Plc has said that it would increase its stakeholding. The British major has also said that it would take up its ownership to 80 per cent in its Nigerian consumer business.
GlaxoSmithKline Plc plans to buy up to an additional 31.8% stake in its Indian consumer products arm for about 52.2 billion rupees ($940 million), as Britain's biggest drugmaker deepens its emerging markets and non-prescription consumer health
GlaxoSmithKline is holding talks this weekend with Human Genome Sciences to agree a deal to acquire it for some $2.6 billion, after pursuing the US biotech firm for three months, sources familiar with the situation said on Sunday.